[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]

Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001402
Original Title: Dimetilfumarato en esclerosis múltiple: comparación de las diferentes marcas comerciales disponibles en Argentina
Authors' recomendations: CONCLUSIONS No evidence was found comparing the four trademarks of commercially available dimethyl-fumarate in Argentina: Tecfidera® (Biogen), Catira® (Bagó), Dimeful® (Gador) and Tilmurato® (Tuteur). Based on the Argentine National Agency for Drugs, Food and Medical Technology (ANMAT), the four trademarks contain the same drug, at the same dose and they are approved for the same indications. The pivotal clinical trials leading to dimethyl fumarate approval have been conducted with the original trademark Tecfidera®. No clinical trials with Catira®, Dimeful® or Tilmurato® have been found.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Multiple Sclerosis
  • Dimethyl Fumarate
  • Drug Therapy
  • Immunosuppressive Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.